用于 PARP1 抑制剂的战略交付的脂质体配方:开发和优化
Carlota J F Conceição1,2, Elin Moe3,4, Paulo A Ribeiro2
1CEFITEC, Department of Physics, NOVA School of Science and Technology, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal.
Nanomaterials (Basel, Switzerland)
|May 27, 2023
概括
研究人员开发了一种针对多 (ADP-ribose) 聚合酶1 (PARP1) 抑制剂的新型脂质纳米递送系统,实现了高封装效率和受控的药物释放,以提高治疗潜力.
科学领域:
- 纳米技术 纳米技术
- 制药科学 制药科学
- 药物输送系统 药物输送系统
背景情况:
- 多 (ADP-ribose) 聚合酶1 (PARP1) 抑制剂在癌症治疗中至关重要.
- 需要有效的输送系统来提高PARP1抑制剂的疗效.
- 维利帕里布,鲁卡帕里布和尼拉帕里布是具有治疗潜力的关键PARP1抑制剂.
研究的目的:
- 为Veliparib,Rucaparib和Niraparib开发和描述一种脂质纳米输送系统.
- 评估开发的纳米配方的封装效率,颗粒大小和药物释放动力学.
- 研究PARP1抑制剂与脂质纳米输送系统之间的相互作用机制.
主要方法:
- 薄膜水化方法用于开发简单和双重脂质配方.
- 纳米颗粒的配方使用1,2-dipalmitoyl-sn-glycero-3-phospho-rac-(1'-glycerol) 盐 (DPPG) 和1,2-dipalmitoyl-sn-glycero-3-phosphocoline (DPPC) 的方法.
- 使用封装效率,泽塔潜力,粒子大小分析,动力释放研究和光谱分析进行表征.
主要成果:
- DPPG封装抑制剂显示出高封装效率 (> 40%) 和合适的泽塔电位 (< -30 mV).
- 开发的纳米粒子具有大约130纳米的粒子大小,具有单一的人口特征.
- 与脂质体对照相比,DPPG封装PARP1抑制剂的药物释放速度较慢,并确定了复杂的释放机制.
- 谱分析表明,PARP1抑制剂与DPPG脂质膜之间通过键发生相互作用.
结论:
- 基于DPPG的脂质纳米输送系统有效地封装了PARP1抑制剂Veliparib,Rucaparib和Niraparib.
- 纳米配方提供受控的药物释放和增强的稳定性.
- PARP1 抑制剂与 DPPG 脂质膜相互作用,这表明一种特定的封装机制涉及质子胺基和脂质碳基.
更多相关视频
相关概念视频
01:27Bioavailability Enhancement: Drug Permeability Enhancement
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...